olfactory receptor family 1 subfamily L member 6Genealiases: HG16 · OR1L7 · OR9-30
Q-omics provides the consensus-scored OR1L6 profile across patient tissues and cancer cell-line models. OR1L6 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, OR1L6 is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, OR1L6 RNA expression shows 8,286 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, STAD, and GBM as cancer lineages where OR1L6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1L6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1L6 survival associations across molecular data types. OR1L6 RNA expression shows survival associations in the most cancer types (7), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1L6 RNA expression–survival associations across cancer types. High OR1L6 expression shows unfavorable associations in UCEC, THCA, UVM, OV and LIHC, but favorable associations in SCLC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify UCEC as the clearest survival context for OR1L6 RNA expression.
This table summarizes OR1L6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR1L6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1L6 shows lower tumor expression in STAD. The STAD box plot shows higher OR1L6 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p = .044).
This table shows molecular features associated with OR1L6 in patient tissues and cancer cell lines. In patient samples, OR1L6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR1L6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and STOMACH.
